mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer

Ionizing radiation (IR) is used frequently in the management of multiple tumor types, including both organ-confined and locally advanced prostate cancer (PCa). Enhancing tumor radiosensitivity could both reduce the amount of radiation required for definitive treatment and improve clinical outcome. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiewer, Matthew J, Den, Robert, Hoang, David T, Augello, Michael A, Lawrence, Yaacov R, Dicker, Adam P, Knudsen, Karen E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Endocrinology 2012
Materias:
Regular Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253653/
https://www.ncbi.nlm.nih.gov/pubmed/21903859
http://dx.doi.org/10.1530/ERC-11-0072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253653/
https://www.ncbi.nlm.nih.gov/pubmed/21903859
http://dx.doi.org/10.1530/ERC-11-0072

Ejemplares similares